ATE430572T1 - Verwendung von spongosin (2-methoxyadenosin) zur behandlung von schmerzen, insbesondere hyperalgesie - Google Patents

Verwendung von spongosin (2-methoxyadenosin) zur behandlung von schmerzen, insbesondere hyperalgesie

Info

Publication number: ATE430572T1
Authority: AT; Austria
Prior art keywords: methoxyadenosine; treatment; pain; spongosin; hyperalgesia
Prior art date: 2002-12-09

Application number

AT03780370T

Other languages

English (en)

Inventor

Peter Richardson

Original Assignee

Cambridge Biotechnology Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-12-09

Filing date

2003-12-09

Publication date

2009-05-15

2003-12-09 Application filed by Cambridge Biotechnology Ltd filed Critical Cambridge Biotechnology Ltd

2009-05-15 Application granted granted Critical

2009-05-15 Publication of ATE430572T1 publication Critical patent/ATE430572T1/de

Links

AJACDNCVEGIBNA-KQYNXXCUSA-N (2r,3r,4s,5r)-2-(6-amino-2-methoxypurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C12=NC(OC)=NC(N)=C2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O AJACDNCVEGIBNA-KQYNXXCUSA-N 0.000 title abstract 5
AJACDNCVEGIBNA-UHFFFAOYSA-N 2-Methoxyadenosine Natural products C12=NC(OC)=NC(N)=C2N=CN1C1OC(CO)C(O)C1O AJACDNCVEGIBNA-UHFFFAOYSA-N 0.000 title abstract 5
208000004454 Hyperalgesia Diseases 0.000 title 1
208000035154 Hyperesthesia Diseases 0.000 title 1
150000003838 adenosines Chemical class 0.000 abstract 1
230000000202 analgesic effect Effects 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Mechanical Treatment Of Semiconductor (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

AT03780370T 2002-12-09 2003-12-09 Verwendung von spongosin (2-methoxyadenosin) zur behandlung von schmerzen, insbesondere hyperalgesie ATE430572T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0228723.3A GB0228723D0 (en)	2002-12-09	2002-12-09	Treatment of pain
PCT/GB2003/005379 WO2004052377A1 (en)	2002-12-09	2003-12-09	Use of spongosine (2-methoxyadenosein) for the treatment of pain, in particular hyperalgesia

Publications (1)

Publication Number	Publication Date
ATE430572T1 true ATE430572T1 (de)	2009-05-15

Family

ID=9949371

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT03780370T ATE430572T1 (de)	2002-12-09	2003-12-09	Verwendung von spongosin (2-methoxyadenosin) zur behandlung von schmerzen, insbesondere hyperalgesie

Country Status (18)

Country	Link
US (2)	US8252766B2 (de)
EP (1)	EP1581235B1 (de)
JP (2)	JP4836454B2 (de)
KR (1)	KR101122495B1 (de)
CN (2)	CN101264097B (de)
AT (1)	ATE430572T1 (de)
AU (1)	AU2003288451B2 (de)
CA (1)	CA2507918A1 (de)
CY (1)	CY1109229T1 (de)
DE (1)	DE60327557D1 (de)
DK (1)	DK1581235T3 (de)
ES (1)	ES2326532T3 (de)
GB (2)	GB0228723D0 (de)
NO (1)	NO20053042L (de)
NZ (1)	NZ540353A (de)
PT (1)	PT1581235E (de)
SI (1)	SI1581235T1 (de)
WO (1)	WO2004052377A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0228723D0 (en)	2002-12-09	2003-01-15	Cambridge Biotechnology Ltd	Treatment of pain
GB0305149D0 (en) *	2003-03-07	2003-04-09	Cambridge Biotechnology Ltd	Compounds for the treatment of pain
MXPA06010075A (es) *	2004-03-05	2007-04-10	Cambridge Biotechnology Ltd	Compuestos terapeuticos.
PE20060272A1 (es)	2004-05-24	2006-05-22	Glaxo Group Ltd	(2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
GB0426394D0 (en)	2004-12-01	2005-01-05	Health Prot Agency	Fusion proteins
US8399400B2 (en)	2004-12-01	2013-03-19	Syntaxin, Ltd.	Fusion proteins
US8778634B2 (en)	2004-12-01	2014-07-15	Syntaxin, Ltd.	Non-cytotoxic protein conjugates
US8603779B2 (en)	2004-12-01	2013-12-10	Syntaxin, Ltd.	Non-cytotoxic protein conjugates
US8512984B2 (en)	2004-12-01	2013-08-20	Syntaxin, Ltd.	Non-cytotoxic protein conjugates
GB0514809D0 (en)	2005-07-19	2005-08-24	Glaxo Group Ltd	Compounds
GB0610867D0 (en)	2006-06-01	2006-07-12	Syntaxin Ltd	Treatment of pain
US7807685B2 (en)	2006-06-27	2010-10-05	Cbt Development Limited	Therapeutic compounds
CA2654371A1 (en)	2006-06-27	2008-01-03	Biovitrum Ab (Publ)	Therapeutic compounds
ES2361886T3 (es)	2006-06-27	2011-06-24	Cbt Development Limited	Profármacos adenosina acetil 2',3'-metilideno novedosos para uso como profármacos para agonistas del receptor adenosina.
AU2009204084A1 (en) *	2008-01-09	2009-07-16	Trovis Pharmaceuticals Llc	Intrathecal treatment of neuropathic pain with A2AR agonists
US8221791B1 (en)	2008-12-10	2012-07-17	University Of Central Florida Research Foundation, Inc.	Silica-based antibacterial and antifungal nanoformulation
CA2766937A1 (en) *	2009-07-09	2011-01-13	Cbt Development Limited	Combined preparation for use as a medicament
WO2011143442A1 (en) *	2010-05-12	2011-11-17	Trovis Pharmaceuticals, Llc.	A method of treating multiple sclerosis with adenosine receptor agonists
EP2631345B1 (de) *	2012-02-27	2019-09-04	Electrolux Home Products Corporation N.V.	Waschwanneneinheit und Waschmaschine
US20140056870A1 (en)	2012-08-27	2014-02-27	Allergan, Inc.	Fusion proteins
WO2017136717A1 (en) *	2016-02-04	2017-08-10	The Johns Hopkins University	Rapadocins, inhibitors of equilibrative nucleoside transporter 1 and uses thereof
US11066416B2 (en)	2016-02-04	2021-07-20	The Johns Hopkins University	Rapafucin derivative compounds and methods of use thereof

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BE792155A (fr)	1971-12-01	1973-05-30	Takeda Chemical Industries Ltd	Nouveaux derives de l'adenosine et leur procede de production
JPS4861498A (de)	1971-12-01	1973-08-28
DE2359536C2 (de)	1972-12-08	1984-08-02	Takeda Chemical Industries, Ltd., Osaka	2,6-Diaminonebularinderivate
JPS5549594B2 (de)	1972-12-08	1980-12-12
JPS5461194A (en)	1977-10-21	1979-05-17	Takeda Chem Ind Ltd	Preparation of n22substituted 2*66diaminonebularin
JPS5461195A (en)	1977-10-21	1979-05-17	Takeda Chem Ind Ltd	N2-substituted phenyl-2,6-diaminonebularin
US4705758A (en)	1984-06-19	1987-11-10	Warner-Lambert Company	Adenosine receptor assay and kit
US5104859A (en) *	1985-09-24	1992-04-14	Solimedco Aktiebolag	Continuous administration of adenosine to reduce pulmonary vascular resistance
US5231086A (en) *	1985-09-24	1993-07-27	Item Development Aktiebolag	Continuous administration adenosine to increase myocardial blood flow
US5310732A (en)	1986-02-03	1994-05-10	The Scripps Research Institute	2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
US5140015A (en)	1990-02-20	1992-08-18	Whitby Research, Inc.	2-aralkoxy and 2-alkoxy adenosine derivatives as coronary vasodilators and antihypertensive agents
US5677290A (en) *	1990-05-10	1997-10-14	Fukunaga; Atsuo F.	Therapeutic use of adenosine compounds as surgical anesthetics
US6180616B1 (en) *	1990-05-10	2001-01-30	Atsuo F. Fukunaga	Use of purine receptor agonists to alleviate or normalize physiopathologically excited sensory nerve function
US6004945A (en) *	1990-05-10	1999-12-21	Fukunaga; Atsuo F.	Use of adenosine compounds to relieve pain
US5679650A (en) *	1993-11-24	1997-10-21	Fukunaga; Atsuo F.	Pharmaceutical compositions including mixtures of an adenosine compound and a catecholamine
AU6516494A (en)	1993-04-15	1994-11-08	New York University	Adenosine receptor agonists for the promotion of wound healing
US5683989A (en) *	1993-12-17	1997-11-04	Novo Nordisk A/S	Treatment of ischemias by administration of 2,N6 -substituted adenosines
SE9401499D0 (sv)	1994-05-02	1994-05-02	Item Dev Ab	New method of treatment
FI964468A0 (fi)	1994-05-10	1996-11-06	Sandoz Ltd	Adenosiinijohdannaisia
US5596094A (en)	1994-05-26	1997-01-21	Sandoz Ltd.	Process for preparing 2' -0- alkyl adenosine derivatives
US5877180A (en)	1994-07-11	1999-03-02	University Of Virginia Patent Foundation	Method for treating inflammatory diseases with A2a adenosine receptor agonists
IT1275420B (it)	1995-06-02	1997-08-05	Schering Plough S P A	Metodo per misurare l'affinita' di legame al recettore a2a dell'adenosina di componenti di interesse farmacologico mediante l'uso del ligando triziato (3h)-sch 58261
WO1998052611A1 (en)	1997-05-23	1998-11-26	Nippon Shinyaku Co., Ltd.	Medicinal composition for prevention or treatment of hepatopathy
US6110902A (en)	1997-06-23	2000-08-29	Moehler; Hanns	Method for the inhibition of neuronal activity leading to a focal epileptic seizure by local delivery of adenosine
JP2003517423A (ja)	1997-07-29	2003-05-27	メドコリサーチ、インコーポレイテッド	アデノシンレセプターモジュレーターとしてのｎ６−置換アデノシン−５′−ウロナミド
US6440455B1 (en)	1997-09-02	2002-08-27	Children's Medical Center Corporation	Methods for modulating the axonal outgrowth of central nervous system neurons
GB9723590D0 (en)	1997-11-08	1998-01-07	Glaxo Group Ltd	Chemical compounds
EP1044004A1 (de)	1998-01-08	2000-10-18	The University Of Virginia Patent Foundation	A2a adenosin rezeptor agonisten in kombination mit typ iv phosphodiesterase inhibitoren
GB9913932D0 (en)	1999-06-15	1999-08-18	Pfizer Ltd	Purine derivatives
US20030008841A1 (en)	2000-08-30	2003-01-09	Rene Devos	Anti-HCV nucleoside derivatives
GB0228723D0 (en)	2002-12-09	2003-01-15	Cambridge Biotechnology Ltd	Treatment of pain
WO2004056180A1 (en)	2002-12-23	2004-07-08	Global Cardiac Solutions Pty Ltd	Organ preconditioning, arrest, protection, preservation and recovery (1)
GB0305149D0 (en) *	2003-03-07	2003-04-09	Cambridge Biotechnology Ltd	Compounds for the treatment of pain
GB0305150D0 (en) *	2003-03-07	2003-04-09	Cambridge Biotechnology Ltd	Use of therapeutic compounds
GB0305153D0 (en)	2003-03-07	2003-04-09	Cambridge Biotechnology Ltd	Identification of therapeutic compounds
MXPA06010075A (es)	2004-03-05	2007-04-10	Cambridge Biotechnology Ltd	Compuestos terapeuticos.
US8407664B2 (en)	2005-12-30	2013-03-26	Sap Ag	Software model business objects

2002
- 2002-12-09 GB GBGB0228723.3A patent/GB0228723D0/en not_active Ceased
2003
- 2003-12-09 CA CA002507918A patent/CA2507918A1/en not_active Abandoned
- 2003-12-09 CN CN2008100922507A patent/CN101264097B/zh not_active Expired - Fee Related
- 2003-12-09 JP JP2004558826A patent/JP4836454B2/ja not_active Expired - Fee Related
- 2003-12-09 CN CNB2003801055073A patent/CN100471503C/zh not_active Expired - Fee Related
- 2003-12-09 WO PCT/GB2003/005379 patent/WO2004052377A1/en not_active Ceased
- 2003-12-09 SI SI200331633T patent/SI1581235T1/sl unknown
- 2003-12-09 EP EP03780370A patent/EP1581235B1/de not_active Expired - Lifetime
- 2003-12-09 PT PT03780370T patent/PT1581235E/pt unknown
- 2003-12-09 DE DE60327557T patent/DE60327557D1/de not_active Expired - Lifetime
- 2003-12-09 AU AU2003288451A patent/AU2003288451B2/en not_active Ceased
- 2003-12-09 AT AT03780370T patent/ATE430572T1/de active
- 2003-12-09 DK DK03780370T patent/DK1581235T3/da active
- 2003-12-09 NZ NZ540353A patent/NZ540353A/en not_active IP Right Cessation
- 2003-12-09 GB GB0328548A patent/GB2396108B/en not_active Expired - Fee Related
- 2003-12-09 US US10/537,564 patent/US8252766B2/en not_active Expired - Fee Related
- 2003-12-09 KR KR1020057010441A patent/KR101122495B1/ko not_active Expired - Fee Related
- 2003-12-09 ES ES03780370T patent/ES2326532T3/es not_active Expired - Lifetime
2005
- 2005-06-21 NO NO20053042A patent/NO20053042L/no not_active Application Discontinuation
2009
- 2009-07-14 CY CY20091100733T patent/CY1109229T1/el unknown
2010
- 2010-08-20 US US12/859,932 patent/US20110184065A1/en not_active Abandoned
- 2010-12-03 JP JP2010270287A patent/JP2011132229A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
CA2507918A1 (en)	2004-06-24
DE60327557D1 (de)	2009-06-18
ES2326532T3 (es)	2009-10-14
DK1581235T3 (da)	2009-08-31
CN101264097B (zh)	2011-10-05
AU2003288451B2 (en)	2009-06-04
GB0328548D0 (en)	2004-01-14
US20110184065A1 (en)	2011-07-28
CN101264097A (zh)	2008-09-17
GB0228723D0 (en)	2003-01-15
NZ540353A (en)	2006-11-30
CN100471503C (zh)	2009-03-25
EP1581235B1 (de)	2009-05-06
PT1581235E (pt)	2009-07-07
WO2004052377A1 (en)	2004-06-24
GB2396108A (en)	2004-06-16
JP2011132229A (ja)	2011-07-07
US8252766B2 (en)	2012-08-28
CN1723026A (zh)	2006-01-18
EP1581235A1 (de)	2005-10-05
JP4836454B2 (ja)	2011-12-14
GB2396108B (en)	2005-08-03
KR20050089815A (ko)	2005-09-08
US20070010475A1 (en)	2007-01-11
SI1581235T1 (sl)	2009-10-31
JP2006514638A (ja)	2006-05-11
HK1086186A1 (zh)	2006-09-15
NO20053042L (no)	2005-06-21
AU2003288451A1 (en)	2004-06-30
KR101122495B1 (ko)	2012-03-15
CY1109229T1 (el)	2013-09-04

Legal Events

Date

Code

Title

Description

2009-11-15

UEP

Publication of translation of european patent specification

Ref document number: 1581235

Country of ref document: EP

Publication	Publication Date	Title
DE60327557D1 (de)	2009-06-18	Verwendung von spongosin (2-methoxyadenosin) zur behandlung von schmerzen, insbesondere hyperalgesie
NZ515567A (en)	2004-03-26	Method for treating chronic pain using MEK inhibitors
MY169308A (en)	2019-03-21	Treatment of tnf? related disorders
ATE250932T1 (de)	2003-10-15	Verfahren zur behandlung von chronischem schmerz durch verabreichung von einem mek hemmer
EP1670450B8 (de)	2011-03-23	Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
ATE524125T1 (de)	2011-09-15	Platte und schrauben zur behandlung von knochenfrakturen
MXPA05005107A (es)	2005-10-19	Composiciones y metodos para el diagnostico y tratamiento de tumores.
MXPA05005223A (es)	2010-09-07	Diaminotriazoles utiles como inhibidores de proteinas cinasas.
WO2006052718A8 (en)	2007-02-08	Farnesyltransferase inhibitors for treating sepsis
MXPA05006359A (es)	2006-02-08	Tratamiento de la enfermedad a traves de inhibidores peptidos antimicrobianos.
MY138732A (en)	2009-07-31	Conjugated complement cascade inhibitors
ATE401087T1 (de)	2008-08-15	Verbindungen zur schmerzbehandlung
DK1648484T3 (da)	2009-01-19	Fremgangsmåde til behandling af arthritis-tilstande
MY141528A (en)	2010-05-14	Anilinopyrazole derivatives useful for the treatment of diabetes
WO2004024064A8 (en)	2005-07-21	Compositions and methods for the diagnosis and treatment of tumor
BR0312470A (pt)	2005-04-26	Composto, uso do mesmo, composição farmacêutica, método de tratar e/ou prevenir câncer, e, processo para preparar o composto
DE60334094D1 (de)	2010-10-21	Verwendung von pleuromutilinen zur behandlung von erkrankungen, die durch helicobacter pylori verursacht werden
ATE453386T1 (de)	2010-01-15	Polyamin-verbindungen zur behandlung von chemokin-rezeptor-vermittelten krankheiten
ATE392212T1 (de)	2008-05-15	Verwendung eines proteasom-inhibitors zur behandlung fibrotischer erkrankungen
EA200600989A1 (ru)	2006-10-27	Применение габоксадола для лечения бессонницы
MXPA05010800A (es)	2005-12-14	Acidos hidroxamicos utiles en el tratamiento de trastornos hiperproliferativos.
ATE412411T1 (de)	2008-11-15	Pmcol zur behandlung von prostatakrebs
ATE486594T1 (de)	2010-11-15	Methode zur behandlung von herzinsuffizienz
TW200642688A (en)	2006-12-16	New use of PDE7 inhibitors
DE60326348D1 (de)	2009-04-09	Makrozyclen zur behandlung von krebserkrankungen